Thank you for considering The Lyon Firm. At this time, we are not accepting plaintiffs related to this specific consumer issue. However, if you would like to be contacted in the future, please complete the contact form. By completing the form you will be contacted if the Firm begins accepting new cases on this matter, and you will also be included in firm news alerts related to important consumer safety and privacy issues to help keep you informed about related issues.
Beovu (brolucizumab-dbll), manufactured by Novartis since October 2019, and used to treat wet macular degeneration, is now suspected of causing irreversible eye damage. New data suggests patients who had specific eye problems before getting treated with Beovu may have a higher risk of vision-threatening conditions after treatment. The Swiss drugmaker has released new information based on a recent safety review.
Beovu is used to treat wet macular degeneration, a relatively common chronic eye disorder caused by abnormal blood vessel growth in the eye that leak fluid or blood into the macula, a portion of the retina responsible for central vision. The condition inhibits proteins used to stimulate the growth of new blood vessels in the eye.
If you have had Beovu treatments and suffered from any eye injury or complication, contact The Lyon to review your case. The firm has engaged some of the largest drug companies in the world and settled injury cases on behalf of plaintiffs nationwide.
Wet Macular Degeneration Symptoms
According to Mayo Clinic, wet AMD causes symptoms that can appear suddenly and may worsen rapidly:
- Visual distortions
- Reduced central vision in one or both eyes
- Decreased vividness or color brightness
- A defined blurry or blind spot in your vision
- A general cloudiness in overall vision
Beovu Vision Loss Warning
The American Society of Retinal Specialists has warned about instances of intraocular inflammation, some of which led to vision loss in patients taking Beovu.
According to Novartis’s own clinical review, the highest risk for experiencing retinal vasculitis or retinal vascular occlusion after first treatment was prior intraocular inflammation or vascular occlusion in the year prior to the first Beovu treatment.
The overall complications risk rate was 0.46% for all patients, and the risk increased to 3.97% in people who had the conditions before Beovu treatment. In June 2020, the U.S. Food and Drug Administration (FDA) approved a label update for Beovu® (brolucizumab) to include additional safety information regarding retinal vasculitis and retinal vascular occlusion. The update to the label includes a sub-section discussing retinal vasculitis and retinal vascular occlusion under “Warnings and Precautions.”
The Lyon Firm is also investigating vision loss lawsuits related to Elmiron, which may cause a rare eye disorder called retinal pigmentary maculopathy.
